36 related articles for article (PubMed ID: 31569304)
1. Phase 2 study of bosutinib, a Src inhibitor, in adults with recurrent glioblastoma.
Taylor JW; Dietrich J; Gerstner ER; Norden AD; Rinne ML; Cahill DP; Stemmer-Rachamimov A; Wen PY; Betensky RA; Giorgio DH; Snodgrass K; Randall AE; Batchelor TT; Chi AS
J Neurooncol; 2015 Feb; 121(3):557-63. PubMed ID: 25411098
[TBL] [Abstract][Full Text] [Related]
2. SKI-606, an Src inhibitor, reduces tumor growth, invasion, and distant metastasis in a mouse model of thyroid cancer.
Kim WG; Guigon CJ; Fozzatti L; Park JW; Lu C; Willingham MC; Cheng SY
Clin Cancer Res; 2012 Mar; 18(5):1281-90. PubMed ID: 22271876
[TBL] [Abstract][Full Text] [Related]
3. Bosutinib Stimulates Macrophage Survival, Phagocytosis, and Intracellular Killing of Bacteria.
da Silva RAG; Stocks CJ; Hu G; Kline KA; Chen J
ACS Infect Dis; 2024 May; 10(5):1725-1738. PubMed ID: 38602352
[TBL] [Abstract][Full Text] [Related]
4. Antitumor effects of immunotoxins are enhanced by lowering HCK or treatment with SRC kinase inhibitors.
Liu XF; Xiang L; FitzGerald DJ; Pastan I
Mol Cancer Ther; 2014 Jan; 13(1):82-9. PubMed ID: 24145282
[TBL] [Abstract][Full Text] [Related]
5. Repurposing of FDA approved kinase inhibitor bosutinib for mitigation of radiation induced damage via inhibition of JNK pathway.
Singh B; Patwardhan RS; Pal D; Maurya DK; Singh BG; Checker R; Sharma D; Sandur SK
Toxicol Appl Pharmacol; 2024 Jan; 482():116792. PubMed ID: 38142783
[TBL] [Abstract][Full Text] [Related]
6. Sustained activation of the AKT/mTOR and MAP kinase pathways mediate resistance to the Src inhibitor, dasatinib, in thyroid cancer.
Mishall KM; Beadnell TC; Kuenzi BM; Klimczak DM; Superti-Furga G; Rix U; Schweppe RE
Oncotarget; 2017 Nov; 8(61):103014-103031. PubMed ID: 29262541
[TBL] [Abstract][Full Text] [Related]
7. Clinical significance of HDAC1, -2 and -3 expression levels in esophageal squamous cell carcinoma.
Li H; Li H; Waresijiang Y; Chen Y; Li Y; Yu L; Li Y; Liu L
Exp Ther Med; 2020 Jul; 20(1):315-324. PubMed ID: 32536999
[TBL] [Abstract][Full Text] [Related]
8. FYN: emerging biological roles and potential therapeutic targets in cancer.
Peng S; Fu Y
J Transl Med; 2023 Feb; 21(1):84. PubMed ID: 36740671
[TBL] [Abstract][Full Text] [Related]
9. Bosutinib.
Keller G; Schafhausen P; Brümmendorf TH
Recent Results Cancer Res; 2010; 184():119-27. PubMed ID: 20072835
[TBL] [Abstract][Full Text] [Related]
10. Bosutinib: a dual SRC/ABL kinase inhibitor for the treatment of chronic myeloid leukemia.
Keller G; Schafhausen P; Brummendorf TH
Expert Rev Hematol; 2009 Oct; 2(5):489-97. PubMed ID: 21083014
[TBL] [Abstract][Full Text] [Related]
11. Bosutinib Acts as a Tumor Inhibitor via Downregulating Src/NF-κB/Survivin Expression in HeLa Cells.
Yu L; Guo W; Liu L; Zhang G; Zhang F; Qu Y; Liu Y; Li H; Li H
Anat Rec (Hoboken); 2019 Dec; 302(12):2193-2200. PubMed ID: 31569304
[TBL] [Abstract][Full Text] [Related]
12. Novel Src/Abl tyrosine kinase inhibitor bosutinib suppresses neuroblastoma growth via inhibiting Src/Abl signaling.
Bieerkehazhi S; Chen Z; Zhao Y; Yu Y; Zhang H; Vasudevan SA; Woodfield SE; Tao L; Yi JS; Muscal JA; Pang JC; Guan S; Zhang H; Nuchtern JG; Li H; Li H; Yang J
Oncotarget; 2017 Jan; 8(1):1469-1480. PubMed ID: 27903968
[TBL] [Abstract][Full Text] [Related]
13. Second-generation Src/Abl inhibitor bosutinib effectively induces apoptosis in human esophageal squamous cell carcinoma (ESCC) cells via inhibiting Src/Abl signaling.
Ha YNE; Dai Y; Wufuer D; Pidayi M; Anasihan G; Chen L
Neoplasma; 2020 Jan; 67(1):54-60. PubMed ID: 31777258
[TBL] [Abstract][Full Text] [Related]
14. Src as a Therapeutic Target in Biliary Tract Cancer.
Nam AR; Kim JW; Park JE; Bang JH; Jin MH; Lee KH; Kim TY; Han SW; Im SA; Kim TY; Oh DY; Bang YJ
Mol Cancer Ther; 2016 Jul; 15(7):1515-24. PubMed ID: 27196758
[TBL] [Abstract][Full Text] [Related]
15. Bosutinib Inhibits EGFR Activation in Head and Neck Cancer.
Segrelles C; Contreras D; Navarro EM; Gutiérrez-Muñoz C; García-Escudero R; Paramio JM; Lorz C
Int J Mol Sci; 2018 Jun; 19(7):. PubMed ID: 29933569
[TBL] [Abstract][Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
